Abstract: 【Abstract】 Objective To investigate clinical efficacy and safety of cultured autologous melanocyte transplantation for the treatment of non-segmental vitiligo accompanied by autoimmune thyroid diseases. Methods From May 2008 to December 2018, a total of 2 284 patients with non-segmental vitiligo were retrospectively collected, who received cultured autologous melanocyte transplantation in Hangzhou Third People′s Hospital. Among these patients, 75 were also diagnosed with autoimmune thyroid diseases, including hyperthyroidism （42 cases）, hypothyroidism （18 cases） and Hashimoto′s thyroiditis （15 cases）. Efficacy and safety were compared between the vitiligo patients with autoimmune thyroid diseases （concomitant group） and those without （non-concomitant group）. Chi-square test was used to compare enumeration data. Results Among the 2 284 patients, 1 085 were males and 1 199 were females, with an age of 25.0 ± 1.2 years and a disease duration of 5.1 ± 2.3 years. Six months after transplantation, 1 873 out of 2 209 patients in the non-concomitant group achieved favorable clinical response, with a response rate of 84.8%, including 1 162 achieving complete clinical response （52.6%）; 46 out of 75 patients in the concomitant group achieved favorable clinical response, with a response rate of 61.3%, including 20 achieving complete clinical response （26.7%）; the response rate and recovery rate were both significantly lower in the concomitant group than in the non-concomitant group （χ2 = 29.72, 19.54, respectively, both P < 0.001）. Moreover, the response rate was significantly lower in the hypothyroidism group than in the hyperthyroidism group （χ2 = 6.61, P = 0.010）. The incidence of isomorphic response at the donor site was significantly higher in the concomitant group than in the non-concomitant group （9.3% vs. 4.3%, χ2 = 4.31, P = 0.038）, so were the recurrence rates of vitiliginous patches at the recipient site after 1, 3, 5 and 10 years （concomitant group: 6.7%, 14.7%, 17.3%, 8.7%, respectively; non-concomitant group: 0.7%, 1.4%, 2.1%, 3.6%, respectively; χ2 = 29.96, 70.69, 67.23, 41.61, respectively, all P < 0.001）. Conclusion Concomitant autoimmune thyroid diseases negatively affect the efficacy of cultured autologous melanocyte transplantation in the treatment of vitiligo, so effective measures should be taken to prevent isomorphic response and recurrence at the recipient site for patients with non-segmental vitiligo complicated by autoimmune thyroid diseases.

Key words: Vitiligo, Cell transplantation, Melanocytes, Hyperthyroidism, Hypothyroidism, Hashimoto disease, Treatment outcome, Recurrence